RNAi技术靶向HBV相关宿主因子治疗慢性乙肝的研究进展  

Progress of RNAi Targeting The Host Genes for Treatment of Chronic HBV Infection

作　　者：赵荣荣 韩秋菊[1] 张建[1] ZHAO Rong-Rong;HAN Qiu-Ju;ZHANG Jian(Institute of Immunopharmaceutical Sciences,School of Pharmaceutical Sciences,Shandong University,Jinan 250012,China;Corresponding author)

机构地区：[1]山东大学药学院免疫药物学研究所,济南250012

出　　处：《生物化学与生物物理进展》2018年第10期997-1005,共9页Progress In Biochemistry and Biophysics

基　　金：国家自然科学基金(81373222;81172789);山东省重点研发计划(2017GSF18159);山东省自然科学基金博士基金(ZR2017BH029)资助项目~~

摘　　要：乙型肝炎病毒(hepatitis B virus,HBV)是一种嗜肝性DNA病毒.HBV慢性感染是导致肝炎、肝硬化以及肝癌的一个重要原因.早期抗HBV研究策略一般是靶向HBV自身进行干预,包括核酸药物、干扰素药物等.然而,由于病毒易突变,且易发生耐药,近年研究者将治疗靶点逐渐转向与HBV入侵、复制及组装等相关的宿主蛋白,这为抗慢性HBV感染治疗带来了新的视野和思路.因此,基于RNAi技术并靶向宿主蛋白抗HBV的策略受到研究者的青睐,并且取得良好的治疗效果.本文将对这一研究领域的最新进展作一综述.Hepatitis B virus, a small DNA virus, is the prototype of the Hepadnaviridae family. Chronic infection with HBV （CHB） remains a significant public health problem in worldwide, which is a major factor resulting in fibrosis, cirrhosis, and hepatocellular. Previous HBV treatment devote to interfere the HBV genome, including nucleotide analogues （NAs） and type I interferon （IFN）. However, virus mutation and drug resistance occur during these treatments. And current therapeutic strategy tend to intervene the host factors, involvement in the entry, replication and assemble of HBV, bringing us a new venue against HBV. Thus, numerous studies spent large amount efforts to explore RNA interference （RNAi） host gene silencers, which potentially could be a novel anti-HBV therapeutics. Here, we summarized the current progression targeting the host genes for curing chronic HBV infection.

关 键 词：HBV 宿主蛋白 RNAI 

分 类 号：R967[医药卫生—药理学]